Core Viewpoint - Rosen Law Firm is urging investors of Capricor Therapeutics, Inc. to contact them regarding a class action lawsuit due to alleged misleading information about the company's business operations and its lead drug candidate, deramiocel [1][2][3]. Summary by Sections Allegations - The lawsuit claims that Capricor provided investors with misleading information about deramiocel, which is intended for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD) [3]. - Defendants allegedly made positive statements about obtaining a Biologics License Application (BLA) from the FDA while concealing adverse facts regarding the safety and efficacy data from the Phase 2 HOPE-2 trial [3]. Class Action Participation - Shareholders wishing to serve as lead plaintiffs must file motions by September 15, 2025, and can remain absent class members if they choose not to participate [4]. - The law firm operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless the case is won [5]. About Rosen Law Firm - Rosen Law Firm is recognized for its leadership in shareholder rights litigation and has recovered over $1 billion for shareholders since its inception [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Capricor Therapeutics, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on September 15, 2025 [1] Group 1: Class Action Details - Investors who purchased Capricor securities between October 9, 2024, and July 10, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by September 15, 2025 [3] - The lawsuit alleges that Capricor provided misleading information regarding its lead drug candidate, deramiocel, which led to artificially inflated stock prices [5] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4] - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, highlighting the firm's expertise in this area [4]

Core Viewpoint - Capricor Therapeutics, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to its lead cell therapy candidate, deramiocel, which is intended for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD) [1][2] Group 1: Lawsuit Details - The lawsuit seeks to recover losses for investors affected by alleged fraud between October 9, 2024, and July 10, 2025 [1] - Defendants allegedly provided misleading information regarding Capricor's ability to obtain a Biologics License Application (BLA) from the FDA for deramiocel while concealing adverse facts about its Phase 2 HOPE-2 trial data [2] - Following the announcement of a Complete Response Letter (CRL) from the FDA on July 11, 2025, which denied the BLA due to insufficient evidence of effectiveness, Capricor's stock price fell from $11.40 to $7.64 per share [2] Group 2: Next Steps for Investors - Investors who suffered losses during the relevant period have until September 15, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [4]

Core Viewpoint - The Gross Law Firm is notifying shareholders of Capricor Therapeutics, Inc. regarding a potential class action lawsuit due to misleading statements related to the company's drug deramiocel for treating cardiomyopathy associated with Duchenne muscular dystrophy [1][3]. Summary by Relevant Sections Company Information - Capricor Therapeutics, Inc. is involved in developing cell therapy candidates, specifically deramiocel, aimed at treating cardiomyopathy linked to Duchenne muscular dystrophy [3]. Allegations - The complaint alleges that Capricor provided investors with misleading information about deramiocel's potential to secure a Biologics License Application (BLA) from the FDA while concealing adverse facts regarding the drug's safety and efficacy data from its Phase 2 HOPE-2 trial [3]. - Following the announcement of a Complete Response Letter (CRL) from the FDA on July 11, 2025, which denied the BLA due to insufficient evidence of effectiveness and the need for additional clinical data, Capricor's stock price fell from $11.40 to $7.64 per share [3]. Class Action Details - The class period for the lawsuit is defined as October 9, 2024, to July 10, 2025, with a deadline for shareholders to register for the class action set for September 15, 2025 [4]. - Shareholders who register will receive updates on the case's progress through a portfolio monitoring software [4]. Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Capricor Therapeutics, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on September 15, 2025 [1] Group 1: Class Action Details - Investors who purchased Capricor securities between October 9, 2024, and July 10, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by September 15, 2025 [3] - Investors can join the class action by visiting the provided link or contacting the law firm for more information [6] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4] - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [4] Group 3: Case Specifics - The lawsuit alleges that Capricor provided misleading information regarding its lead drug candidate, deramiocel, which is intended for treating cardiomyopathy associated with Duchenne muscular dystrophy [5] - Defendants allegedly made positive statements about obtaining a Biologics License Application from the FDA while concealing adverse facts about the drug's safety and efficacy data from a Phase 2 trial [5] - This misleading information is claimed to have led to shareholders purchasing securities at inflated prices, resulting in damages when the truth was revealed [5]

Core Viewpoint - A shareholder class action lawsuit has been filed against Capricor Therapeutics, Inc. alleging that the company made materially false and misleading statements regarding the safety and efficacy data from its Phase 2 HOPE-2 trial study of deramiocel [1] Group 1 - The lawsuit claims that Capricor failed to disclose material adverse information concerning its four-year safety and efficacy data [1] - The lawsuit specifically targets shareholders who purchased shares between October 9, 2024, and July 10, 2025, and experienced significant losses [2] - The deadline for shareholders to request to be appointed as lead plaintiff in the case is September 15, 2025 [3] Group 2 - Holzer & Holzer, LLC is representing the shareholders in this litigation and has a history of recovering hundreds of millions of dollars for shareholders affected by corporate misconduct [3] - The firm has been recognized as an ISS top-rated securities litigation law firm for the years 2021, 2022, and 2023 [3] - Contact information for the law firm is provided for shareholders seeking to discuss their legal rights [4]

Core Viewpoint - Capricor Therapeutics, Inc. is facing a securities fraud class action lawsuit, with a deadline for investors to join the lawsuit approaching on September 15, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Southern District of California on behalf of investors who purchased or acquired Capricor securities between October 9, 2024, and July 10, 2025, alleging violations of the Securities Exchange Act of 1934 [3]. - The allegations include misrepresentations regarding Capricor's four-year safety and efficacy data from the Phase 2 HOPE-2 trial study of deramiocel, the company's lead cell therapy candidate for treating cardiomyopathy associated with Duchenne muscular dystrophy [4]. Group 2: Investor Participation - Investors wishing to serve as lead plaintiffs must file necessary documents by September 15, 2025, although participation as a lead plaintiff is not required to share in any potential recovery [5]. - All legal representation in this matter is on a contingency fee basis, meaning shareholders will not incur any fees or expenses [5]. Group 3: Law Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since its establishment in 1993 and has represented both individual investors and large public and private pension funds [6]. - The firm has been recognized multiple times for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for sixteen consecutive years [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Capricor Therapeutics, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on September 15, 2025 [1]. Group 1: Class Action Details - Investors who purchased Capricor securities between October 9, 2024, and July 10, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by September 15, 2025 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting their own achievements in this area [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Rosen Law Firm has been recognized for its leadership in securities class action settlements, ranking No. 1 in 2017 and consistently in the top 4 since 2013 [4]. Group 3: Case Specifics - The lawsuit alleges that Capricor provided misleading information regarding its lead cell therapy candidate, deramiocel, which is intended for treating cardiomyopathy associated with Duchenne muscular dystrophy [5]. - Defendants allegedly made positive statements about obtaining a Biologics License Application from the FDA while concealing adverse facts about the drug's safety and efficacy data from its Phase 2 trial [5]. - This misleading information is claimed to have caused shareholders to purchase securities at inflated prices, leading to investor damages when the truth was revealed [5].

Core Viewpoint - Capricor Therapeutics, Inc. is facing a class action lawsuit due to alleged misleading statements regarding the safety and efficacy of its drug, deramiocel, during the Class Period from October 9, 2024, to July 10, 2025 [1][4]. Group 1: Company Overview - Capricor is a clinical-stage biotechnology company focused on developing cell- and exosome-based therapeutics for Duchenne muscular dystrophy (DMD) and other diseases [3]. Group 2: Allegations and Stock Performance - The lawsuit claims that Capricor made false or misleading statements about the four-year safety and efficacy data from its Phase 2 HOPE-2 trial, leading to a false impression of potential approval for DMD cardiomyopathy [4]. - On May 5, 2025, Capricor reported completion of a mid-cycle review with the FDA, which led to a stock drop of over 29% [5]. - Following a report on June 20, 2025, regarding skepticism from the FDA about deramiocel's efficacy and safety, Capricor's stock fell more than 30% [6]. - On July 11, 2025, Capricor announced it received a Complete Response Letter from the FDA denying its Biologics License Application for deramiocel, resulting in a nearly 33% drop in stock price [7].

Core Viewpoint - A class action has been filed against Capricor Therapeutics, Inc. for allegedly misleading investors regarding the viability of its lead product candidate, deramiocel, for treating Duchenne muscular dystrophy (DMD) [1][2]. Group 1: Company Overview - Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cell and exosome-based therapeutics for DMD and other diseases with unmet medical needs in the U.S. [1] - The company's lead product candidate is deramiocel, which consists of allogeneic cardiosphere-derived cells [1]. Group 2: Allegations and Legal Action - Robbins LLP is investigating allegations that Capricor misled investors about deramiocel's potential for first approval for DMD cardiomyopathy while concealing adverse safety and efficacy data from its Phase 2 HOPE-2 trial [2]. - The complaint states that the misleading information led to shareholders purchasing Capricor's securities at artificially inflated prices [2]. Group 3: Stock Price Impact - On July 11, 2025, Capricor announced it received a Complete Response Letter (CRL) from the FDA, denying its Biologics License Application due to insufficient evidence of effectiveness and the need for additional clinical data [3]. - Following the announcement, Capricor's stock price fell from $11.40 per share on July 10, 2025, to $7.64 per share on July 11, 2025 [3].